GLP1 Academy

Free course · 12 modules

GLP-1 Longevity Course

What GLP-1 medications can — and can't — do for healthy aging. Short, evidence-based lessons that separate proven benefits from hype.

Module 1

What Exactly Is a GLP-1?

GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. It belongs to a family called incretins, which help your body handle a meal.

What natural GLP-1 does

  • • Increases insulin release, but only when blood sugar is elevated (glucose-dependent)
  • • Reduces glucagon, a hormone that raises blood sugar
  • • Slows how quickly the stomach empties
  • • Acts on appetite and fullness pathways in the brain

Your own GLP-1 lasts only minutes. GLP-1 receptor agonist medications are engineered to activate the same receptor for far longer, which is why their effects on appetite and blood sugar are much stronger.

The major medications

  • • Semaglutide — Ozempic / Wegovy
  • • Liraglutide — Victoza / Saxenda
  • • Dulaglutide — Trulicity
  • • Tirzepatide — Mounjaro / Zepbound (technically a dual GIP/GLP-1 receptor agonist)

Longevity takeaway

GLP-1 drugs weren't developed as longevity therapies. The interest emerged because the conditions they improve — obesity, diabetes, cardiovascular disease and kidney disease — are major drivers of disability and early death.

Module 2

GLP-1s and the Biology of Aging

It's important to separate how a drug might work (mechanism) from what it has actually been proven to do (outcomes).

Proposed longevity pathways

  • • Less visceral (deep belly) fat
  • • Better insulin sensitivity and blood sugar control
  • • Lower cardiometabolic risk
  • • Lower markers of systemic inflammation
  • • Improved blood pressure and lipid-related risk factors
  • • Fewer cardiovascular events in selected populations
  • • Potential kidney protection

Healthspan ≠ lifespan

A drug can reduce disease risk without having been shown to slow biological aging itself.

Evidence level

  • • Strong: obesity, diabetes, cardiovascular and kidney outcomes in specific populations
  • • Emerging: inflammation, liver disease and some other age-related disease pathways
  • • Unproven: general anti-aging, slowing biological aging, increasing maximum lifespan, or extending lifespan in otherwise healthy people

Module 3

Weight, Visceral Fat and Metabolic Health

This is the foundation of the longevity argument. Visceral fat — the fat around your organs — matters far more for health than simply looking thinner.

Excess visceral fat is associated with

  • • Insulin resistance
  • • Type 2 diabetes
  • • Cardiovascular disease
  • • Fatty liver disease
  • • Chronic inflammation
  • • Sleep apnea
  • • Mobility limitations

In a STEP 1 body-composition substudy, people taking semaglutide lost about 15% of body weight, with roughly 19% less total fat mass and 27% less visceral fat.

The trade-off

Lean body mass also fell by about 9.7% in that substudy — even though lean mass rose as a share of total body weight. That leads directly to the most important module in this course.

Unlock the full course — free

Continue with Modules 4–12

  • 🔒 4. The Muscle Problem: Losing Fat Without Becoming Frail
  • 🔒 5. GLP-1s and Cardiovascular Longevity
  • 🔒 6. Diabetes Prevention and Metabolic Longevity
  • 🔒 7. Kidney Protection
  • 🔒 8. Brain Health: Exciting Hypothesis Meets Reality
  • 🔒 9. Sleep, Sleep Apnea and Healthy Aging
  • 🔒 10. Risks, Side Effects and Who Should Be Careful
  • 🔒 11. The Longevity Lifestyle While Taking a GLP-1
  • 🔒 12. Are GLP-1s Actually Longevity Drugs?

No medical questionnaire. No health information required.

Educational information for adults, not medical advice. This course does not diagnose conditions, determine eligibility or recommend treatment. Talk with your healthcare professional about your own situation.